Overview

Docetaxel in the Treatment of Hormone Refractory Prostate Cancer

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Evaluation of safety and efficacy of docetaxel in the treatment of advanced hormone refractory prostate cancer under the conditions of daily practise.

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Docetaxel
Hormones
Prednisone